Investment analysts at Barclays began coverage on shares of GENFIT S A/ADR (NASDAQ:GNFT) in a research report issued on Monday, Benzinga’s Daily Ratings Newsletter reports. The brokerage set an “overweight” rating and a $55.00 price target on the stock. Barclays‘s price target would indicate a potential upside of 120.18% from the company’s previous close.

GENFIT S A/ADR stock remained flat at $$24.98 during trading on Monday. 2,869 shares of the company were exchanged.

GENFIT S A/ADR Company Profile

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Read More: What is a stock split?

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with's FREE daily email newsletter.